STOCK TITAN

[144] RESMED INC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

ResMed (RMD) filed a Form 144 proposing the sale of 100 shares of common stock through Fidelity Brokerage Services with an approximate market value of $27,436, scheduled for 10/01/2025. The shares were acquired by restricted stock vesting on 11/11/2023 and were granted as compensation. The filer previously sold 66 shares on 07/01/2025 for $16,961.34 and 50 shares on 08/01/2025 for $14,095.00. The filing includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.

ResMed (RMD) ha presentato un Modulo 144 proponendo la vendita di 100 azioni ordinarie tramite Fidelity Brokerage Services, con un valore di mercato approssimativo di 27.436 dollari, prevista per il 01/10/2025. Le azioni sono state acquisite tramite stock soggetti a vesting che matura l'11/11/2023 e sono state concesse come compenso. Il dichiarante ha precedentemente venduto 66 azioni il 01/07/2025 per 16.961,34 dollari e 50 azioni l'01/08/2025 per 14.095,00 dollari. La presentazione include la dichiarazione richiesta secondo cui il venditore non possiede informazioni materiali avverse non divulgate sull'emittente.

ResMed (RMD) presentó un Formulario 144 proponiendo la venta de 100 acciones ordinarias a través de Fidelity Brokerage Services con un valor de mercado aproximado de 27.436 USD, programada para el 01/10/2025. Las acciones se adquirieron mediante acciones restringidas que vencen al vesting el 11/11/2023 y se otorgaron como compensación. El presentante ya vendió 66 acciones el 01/07/2025 por 16.961,34 USD y 50 acciones el 01/08/2025 por 14.095,00 USD. La presentación incluye la representación requerida de que el vendedor no posee información material adversa no divulgada acerca del emisor.

ResMed(RMD)가 Fidelity Brokerage Services를 통해 2025년 10월 1일로 예정된 100주 보통주 매각을 제안하는 Form 144를 제출했습니다. 주식은 2013년 11월 11일에 vesting되는 제한 주식으로 취득되었으며 보상으로 부여되었습니다. 제출자는 이전에 2025년 7월 1일 66주를 16,961.34달러에, 2025년 8월 1일 50주를 14,095.00달러에 매각했습니다. 제출에는 발행인에 관한 비공개적이고 중대한 악재 정보가 없다는 필요한 진술이 포함되어 있습니다.

ResMed (RMD) a déposé un Formulaire 144 proposant la vente de 100 actions ordinaires via Fidelity Brokerage Services, d’une valeur marchande approximative de 27 436 USD, prévue pour le 01/10/2025. Les actions ont été acquises par des actions restreintes qui prennent vesting le 11/11/2023 et ont été accordées en tant que rémunération. Le déclarant a précédemment vendu 66 actions le 01/07/2025 pour 16 961,34 USD et 50 actions le 01/08/2025 pour 14 095,00 USD. Le dépôt inclut la représentation requise selon laquelle le vendeur ne possède pas d’informations matérielles défavorables non divulguées sur l’émetteur.

ResMed (RMD) hat ein Form 144 eingereicht, das den Verkauf von 100 Stammaktien über Fidelity Brokerage Services mit einem ungefähren Marktwert von 27.436 USD ankündigt, geplant für den 01.10.2025. Die Aktien wurden durch eingeschränkte Aktien, die am 11.11.2023 vesten erworben und als Vergütung gewährt. Der Einreicher hat zuvor 66 Aktien am 01.07.2025 für 16.961,34 USD verkauft und 50 Aktien am 01.08.2025 für 14.095,00 USD. Die Einreichung enthält die erforderliche Darstellung, dass der Verkäufer keine unbekannten wesentlichen nachteiligen Informationen über den Emittenten besitzt.

قدمت ResMed (RMD) نموذج Form 144 يقترح بيع 100 سهم من الأسهم العادية عبر Fidelity Brokerage Services بقيمة سوقية تقريبيّة 27,436 دولارًا، المقرر في 01/10/2025. تم الحصول على الأسهم من خلال أسهم مقيدة تكون عندهاVest في 11/11/2023 ومنحت كـ تعويض. قام المُقدم بالبيع سابقًا 66 سهمًا في 01/07/2025 مقابل 16,961.34 دولار و 50 سهمًا في 01/08/2025 مقابل 14,095.00 دولار. يتضمن الملخص التصريح المطلوب بأن البائع لا يملك معلومات جوهرية سلبية غير معلنة عن المصدر.

ResMed (RMD) 提交了 Form 144,拟通过 Fidelity Brokerage Services 出售 100 股普通股,市场价值约为 27,436 美元,计划于 2025/10/01 进行。 这些股份通过 在 2023/11/11 授予归属的受限股票取得,作为 薪酬授予。申报人此前已在 2025/07/01 以 16,961.34 美元卖出 66 股,在 2025/08/01 以 14,095.00 美元卖出 50 股。本次申报包含所需的表述,即卖方对发行人没有未披露的重大不利信息。

Positive
  • Compliance with Rule 144 disclosure requirements by providing broker, acquisition, and sale details
  • Transparency about prior sales on 07/01/2025 and 08/01/2025 with gross proceeds disclosed
Negative
  • None.

Insights

TL;DR: Routine insider Form 144 disclosing a small, post-vesting sale; immaterial to company capitalization.

The filing reports a proposed sale of 100 shares acquired via restricted stock vesting on 11/11/2023 and designated as compensation. The disclosed aggregate market value ($27,436) and the small quantity relative to total outstanding shares (146,414,839) indicate the transaction is unlikely to be materially dilutive or price-moving. Prior recent sales of 66 and 50 shares are listed, consistent with staged dispositions under Rule 144. This appears to be a compliance-driven disclosure of insider sales rather than a company-level operational event.

TL;DR: Filing meets Rule 144 reporting requirements and includes the seller's attestation about material nonpublic information.

The Form 144 supplies required broker, acquisition, and sale details and repeats the statutory attestation concerning material nonpublic information. Acquisition through restricted stock vesting and subsequent scheduled sales align with standard executive compensation monetization practices. From a governance perspective, the filing demonstrates procedural compliance and transparency but does not itself signal governance changes or disclosures of internal issues.

ResMed (RMD) ha presentato un Modulo 144 proponendo la vendita di 100 azioni ordinarie tramite Fidelity Brokerage Services, con un valore di mercato approssimativo di 27.436 dollari, prevista per il 01/10/2025. Le azioni sono state acquisite tramite stock soggetti a vesting che matura l'11/11/2023 e sono state concesse come compenso. Il dichiarante ha precedentemente venduto 66 azioni il 01/07/2025 per 16.961,34 dollari e 50 azioni l'01/08/2025 per 14.095,00 dollari. La presentazione include la dichiarazione richiesta secondo cui il venditore non possiede informazioni materiali avverse non divulgate sull'emittente.

ResMed (RMD) presentó un Formulario 144 proponiendo la venta de 100 acciones ordinarias a través de Fidelity Brokerage Services con un valor de mercado aproximado de 27.436 USD, programada para el 01/10/2025. Las acciones se adquirieron mediante acciones restringidas que vencen al vesting el 11/11/2023 y se otorgaron como compensación. El presentante ya vendió 66 acciones el 01/07/2025 por 16.961,34 USD y 50 acciones el 01/08/2025 por 14.095,00 USD. La presentación incluye la representación requerida de que el vendedor no posee información material adversa no divulgada acerca del emisor.

ResMed(RMD)가 Fidelity Brokerage Services를 통해 2025년 10월 1일로 예정된 100주 보통주 매각을 제안하는 Form 144를 제출했습니다. 주식은 2013년 11월 11일에 vesting되는 제한 주식으로 취득되었으며 보상으로 부여되었습니다. 제출자는 이전에 2025년 7월 1일 66주를 16,961.34달러에, 2025년 8월 1일 50주를 14,095.00달러에 매각했습니다. 제출에는 발행인에 관한 비공개적이고 중대한 악재 정보가 없다는 필요한 진술이 포함되어 있습니다.

ResMed (RMD) a déposé un Formulaire 144 proposant la vente de 100 actions ordinaires via Fidelity Brokerage Services, d’une valeur marchande approximative de 27 436 USD, prévue pour le 01/10/2025. Les actions ont été acquises par des actions restreintes qui prennent vesting le 11/11/2023 et ont été accordées en tant que rémunération. Le déclarant a précédemment vendu 66 actions le 01/07/2025 pour 16 961,34 USD et 50 actions le 01/08/2025 pour 14 095,00 USD. Le dépôt inclut la représentation requise selon laquelle le vendeur ne possède pas d’informations matérielles défavorables non divulguées sur l’émetteur.

ResMed (RMD) hat ein Form 144 eingereicht, das den Verkauf von 100 Stammaktien über Fidelity Brokerage Services mit einem ungefähren Marktwert von 27.436 USD ankündigt, geplant für den 01.10.2025. Die Aktien wurden durch eingeschränkte Aktien, die am 11.11.2023 vesten erworben und als Vergütung gewährt. Der Einreicher hat zuvor 66 Aktien am 01.07.2025 für 16.961,34 USD verkauft und 50 Aktien am 01.08.2025 für 14.095,00 USD. Die Einreichung enthält die erforderliche Darstellung, dass der Verkäufer keine unbekannten wesentlichen nachteiligen Informationen über den Emittenten besitzt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the RMD Form 144 disclose?

The filing discloses a proposed sale of 100 common shares via Fidelity with an aggregate market value of $27,436, approximate sale date 10/01/2025.

How were the 100 shares acquired according to the filing?

The shares were acquired by restricted stock vesting on 11/11/2023 and were granted as compensation.

Has the filer sold other RMD shares recently?

Yes. The filer sold 66 shares on 07/01/2025 for $16,961.34 and 50 shares on 08/01/2025 for $14,095.00.

Who is the broker handling the proposed sale?

The broker listed is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917.

Does the filing state whether the seller has material nonpublic information?

Yes. The seller represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Resmed

NYSE:RMD

RMD Rankings

RMD Latest News

RMD Latest SEC Filings

RMD Stock Data

40.50B
145.52M
0.79%
64.76%
5.81%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO